EA201390453A1 - Человеческие анти-тау антитела - Google Patents

Человеческие анти-тау антитела

Info

Publication number
EA201390453A1
EA201390453A1 EA201390453A EA201390453A EA201390453A1 EA 201390453 A1 EA201390453 A1 EA 201390453A1 EA 201390453 A EA201390453 A EA 201390453A EA 201390453 A EA201390453 A EA 201390453A EA 201390453 A1 EA201390453 A1 EA 201390453A1
Authority
EA
Eurasian Patent Office
Prior art keywords
tau
well
human anti
tau antibodies
variants
Prior art date
Application number
EA201390453A
Other languages
English (en)
Other versions
EA031698B1 (ru
Inventor
Фэн Чэнь
Ян Гримм
Жан-Луи Баерисвиль
Рогер Нитш
Кристоф Хок
Original Assignee
Байоджен Айдек Интернэшнл Нейросайенз Гмбх
Юниверсити Оф Цюрих
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байоджен Айдек Интернэшнл Нейросайенз Гмбх, Юниверсити Оф Цюрих filed Critical Байоджен Айдек Интернэшнл Нейросайенз Гмбх
Publication of EA201390453A1 publication Critical patent/EA201390453A1/ru
Publication of EA031698B1 publication Critical patent/EA031698B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Abstract

Предлагаются новые человеческие тау-специфические антитела, а также их фрагменты, производные и варианты, а также связанные с ними способы. Также раскрыты анализы, наборы и твердые подложки, связанные с антителами, специфическими по отношению к тау. Антитело, иммуноглобулиновая цепь (цепи), а также их связывающие фрагменты, производные и варианты могут быть использованы в фармацевтических и диагностических композициях для нацеленной на тау иммунотерапии и диагностики, соответственно.
EA201390453A 2010-10-11 2011-10-11 Человеческие анти-тау антитела EA031698B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39175110P 2010-10-11 2010-10-11
EP10013494 2010-10-11
PCT/IB2011/002786 WO2012049570A1 (en) 2010-10-11 2011-10-11 Human anti-tau antibodies

Publications (2)

Publication Number Publication Date
EA201390453A1 true EA201390453A1 (ru) 2013-08-30
EA031698B1 EA031698B1 (ru) 2019-02-28

Family

ID=43602869

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201390453A EA031698B1 (ru) 2010-10-11 2011-10-11 Человеческие анти-тау антитела

Country Status (23)

Country Link
US (6) US20130295021A1 (ru)
EP (1) EP2627672B1 (ru)
JP (2) JP2014503178A (ru)
CN (1) CN103339146B (ru)
AU (1) AU2011315181B2 (ru)
BR (1) BR112013008765B8 (ru)
CA (1) CA2813493C (ru)
CY (1) CY1120951T1 (ru)
DK (1) DK2627672T3 (ru)
EA (1) EA031698B1 (ru)
ES (1) ES2686550T3 (ru)
HR (1) HRP20181320T8 (ru)
IL (1) IL225670B (ru)
LT (1) LT2627672T (ru)
MX (1) MX345092B (ru)
NZ (1) NZ609984A (ru)
PL (1) PL2627672T3 (ru)
PT (1) PT2627672T (ru)
SG (1) SG189174A1 (ru)
SI (1) SI2627672T1 (ru)
TR (1) TR201812636T4 (ru)
WO (1) WO2012049570A1 (ru)
ZA (1) ZA201303175B (ru)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL199534A (en) 2007-01-05 2013-01-31 Univ Zuerich An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses.
JP2014503178A (ja) 2010-10-11 2014-02-13 バイオジェン アイデック インターナショナル ニューロサイエンス ゲーエムベーハー ヒト抗タウ抗体
US20120244174A1 (en) 2011-01-31 2012-09-27 Intellect Neurosciences Inc. Treatment of tauopathies
JP6306513B2 (ja) 2011-12-20 2018-04-04 ヤンセン バイオテツク，インコーポレーテツド 抗ＰＨＦ−ｔａｕ抗体及びその使用
CN104781278B (zh) 2012-07-03 2018-06-12 华盛顿大学 针对tau的抗体
WO2014016737A1 (en) * 2012-07-24 2014-01-30 Pfizer Inc. Novel chicken monoclonal antibodies against human phosphorylated tau and uses thereof
MX359817B (es) * 2012-08-16 2018-10-11 Ipierian Inc Anticuerpos que se enlazan a tau.
US20140056901A1 (en) * 2012-08-21 2014-02-27 The Institute For Molecular Medicine Anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies
EA035932B1 (ru) 2012-12-21 2020-09-02 Байоджен Ма Инк. Человеческие анти-тау антитела
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
AU2014248515B2 (en) * 2013-03-13 2019-03-07 Prothena Biosciences Limited Tau immunotherapy
MX2015012872A (es) * 2013-03-15 2016-02-03 Ac Immune Sa Anticuerpos anti-tau y metodos de uso.
PL3007726T3 (pl) * 2013-06-10 2021-01-11 Ipierian, Inc. Metody leczenia tauopatii
GB201312226D0 (en) * 2013-07-08 2013-08-21 Adx Neurosciences Improved antibodies
JP6629201B2 (ja) * 2013-11-27 2020-01-15 アイピエリアン，インコーポレイティド タウオパチーの処置方法
PL3083680T3 (pl) 2013-12-20 2020-06-29 F. Hoffmann-La Roche Ag Humanizowane przeciwciała przeciwko białku tau(pS422) i sposoby stosowania
NZ630610A (en) 2014-02-14 2019-05-31 Ipierian Inc Tau peptides, anti-tau antibodies, and methods of use thereof
ZA201608812B (en) 2014-06-26 2019-08-28 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
AR100978A1 (es) 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
CN107074935B (zh) * 2014-06-26 2021-08-03 扬森疫苗与预防公司 特异性结合微管相关蛋白tau的抗体和抗原结合片段
TWI664190B (zh) * 2014-06-27 2019-07-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗－ｔａｕ抗體
KR102502356B1 (ko) * 2014-09-30 2023-02-21 워싱턴 유니버시티 타우 (tau) 활동 계측
CA3001724A1 (en) * 2014-10-10 2016-04-14 National Research Council Of Canada Anti-tau antibody and uses thereof
EP3786182A1 (en) 2014-11-19 2021-03-03 Axon Neuroscience SE Humanized tau antibodies in alzheimer's disease
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
WO2016137950A1 (en) * 2015-02-24 2016-09-01 Rpeptide, Llc Anti-tau antibodies
AR103713A1 (es) * 2015-02-26 2017-05-31 Lilly Co Eli Anticuerpos contra tau y sus usos
WO2016164530A1 (en) * 2015-04-07 2016-10-13 University Of Maryland, College Park Compositions and methods for high throughput protein sequencing
CN107849124B (zh) 2015-06-05 2021-09-24 基因泰克公司 抗tau抗体及使用方法
EP3313877B1 (en) 2015-06-24 2020-06-03 H. Hoffnabb-La Roche Ag Humanized anti-tau(ps422) antibodies and methods of use
MA41669A1 (fr) 2015-07-06 2018-05-31 Ucb Biopharma Sprl Anticorps se liant a tau
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
CN105388302A (zh) * 2015-12-22 2016-03-09 中国医学科学院输血研究所 一种人免疫球蛋白制品中Tau蛋白抗体含量的检测方法
PL3430397T3 (pl) 2016-03-14 2022-04-04 Biogen International Neuroscience Gmbh Oznaczenie fagocytozy zależnej od przeciwciał do wiarygodnych pomiarów wychwytu zagregowanych białek
KR102471787B1 (ko) 2016-05-02 2022-11-29 프로테나 바이오사이언시즈 리미티드 타우 인식 항체
CN109415434B (zh) 2016-05-02 2022-12-30 普罗塞纳生物科学有限公司 识别tau的抗体
ES2933491T3 (es) 2016-05-02 2023-02-09 Prothena Biosciences Ltd Inmunoterapia tau
IL263433B2 (en) 2016-06-07 2024-03-01 Biogen Int Neuroscience Gmbh Methods for treating Alzheimer's disease
MY197836A (en) 2016-07-12 2023-07-20 H Lundbeck As Antibodies specific for hyperphosphorylated tau and methods of use thereof
JP2018035137A (ja) 2016-07-13 2018-03-08 マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
CA3030754C (en) * 2016-07-20 2022-04-26 Anahit Ghochikyan Humanized anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies
US20190330318A1 (en) 2016-07-25 2019-10-31 Biogen Ma Inc. Anti-hspa5 (grp78) antibodies and uses thereof
WO2018031361A2 (en) 2016-08-09 2018-02-15 Eli Lilly And Company Combination therapy
US11072639B2 (en) 2016-09-08 2021-07-27 Regenerative Research Foundation Bi-functional anti-tau polypeptides and use thereof
CR20230163A (es) 2016-12-07 2023-07-06 Genentech Inc ANTICUERPOS ANTITAU Y MÉTODOS DE USO (Divisional 2019-0271)
AU2017373884A1 (en) 2016-12-07 2019-05-30 Ac Immune Sa Anti-tau antibodies and methods of their use
EP3562840A1 (en) 2016-12-16 2019-11-06 Biogen MA Inc. Stabilized proteolytically activated growth differentiation factor 11
EP3583123A1 (en) 2017-02-17 2019-12-25 Denali Therapeutics Inc. Anti-tau antibodies and methods of use thereof
JP2018139530A (ja) 2017-02-27 2018-09-13 帝人ファーマ株式会社 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
JOP20180021A1 (ar) 2017-03-16 2019-01-30 Janssen Biotech Inc الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها
TW202400231A (zh) 2017-03-28 2024-01-01 美商建南德克公司 治療神經退化性疾病之方法
US11249093B2 (en) * 2017-03-28 2022-02-15 Janssen Vaccines & Prevention B.V. Methods for detection of Tau protein aggregation modulating compounds
KR20190133191A (ko) * 2017-03-28 2019-12-02 얀센 백신스 앤드 프리벤션 비.브이. 타우에 특이적으로 결합하는 결합 분자
CA3061516A1 (en) 2017-05-02 2018-11-08 Prothena Biosciences Limited Antibodies recognizing tau
JP2020529394A (ja) * 2017-06-16 2020-10-08 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ タウオパチーを治療するための組成物及び方法
JP7263320B2 (ja) 2017-08-22 2023-04-24 バイオジェン・エムエイ・インコーポレイテッド 抗ベータアミロイド抗体を含有する医薬組成物
EA202090604A1 (ru) 2017-10-02 2020-10-15 Мерк Шарп энд Доум Корп. Хроманмонобактамовые соединения для лечения бактериальных инфекций
TWI750419B (zh) * 2017-10-16 2021-12-21 日商衛材R&D企管股份有限公司 抗tau抗體及其用途
US20200369754A1 (en) * 2017-12-04 2020-11-26 Janssen Vaccines & Prevention B.V. Binding molecules that specifically bind to tau
WO2019113711A1 (en) 2017-12-14 2019-06-20 University Of Ottawa Exosome packaging and targeted autophagy
WO2019161384A1 (en) * 2018-02-19 2019-08-22 New York University Tau single domain antibodies
NL2020520B1 (en) * 2018-03-02 2019-09-12 Labo Bio Medical Invest B V Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders
CN112105639A (zh) * 2018-03-05 2020-12-18 詹森药业有限公司 抗PHF-tau抗体及其用途
CN111918875A (zh) * 2018-03-11 2020-11-10 库罗什·沙帕桑 构象-特异性的抗神经毒性tau蛋白的抗体
JP2021530552A (ja) 2018-07-31 2021-11-11 イーライ リリー アンド カンパニー 併用療法
MA54070A (fr) 2018-10-29 2021-09-08 Biogen Ma Inc Variants fc5 humanisés et stabilisés pour l'amélioration du transport à travers la barrière hémato-encéphalique
AU2019377595A1 (en) * 2018-11-08 2021-05-27 Prothena Biosciences Limited Antibodies recognizing tau
WO2020180819A1 (en) 2019-03-03 2020-09-10 Prothena Biosciences Limited Antibodies recognizing tau
CA3135170A1 (en) 2019-04-05 2020-10-08 Tauc3 Biologics Limited Anti-tauc3 antibodies and uses thereof
TWI780464B (zh) 2019-08-06 2022-10-11 香港商新旭生技股份有限公司 結合至病理性ｔａｕ種類之抗體及其用途
TWI793451B (zh) * 2019-09-20 2023-02-21 納維再生科技股份有限公司 個人化癌症免疫治療
AR122721A1 (es) 2020-06-25 2022-09-28 Merck Sharp & Dohme Anticuerpos de alta afinidad dirigidos a tau fosforilada en la serina 413
WO2022144406A1 (en) * 2020-12-29 2022-07-07 Neurimmune Ag Human anti-tau antibodies
WO2023028591A1 (en) 2021-08-27 2023-03-02 Genentech, Inc. Methods of treating tau pathologies
WO2023041805A1 (en) 2021-09-20 2023-03-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor
WO2023099788A1 (en) 2021-12-03 2023-06-08 Neurimmune Ag Novel potency assay for antibody-based drugs and useful means therefor
WO2023178049A1 (en) 2022-03-14 2023-09-21 Genentech, Inc. Predicting neurodegenerative diseases based on speech analyses
WO2023250326A1 (en) 2022-06-21 2023-12-28 Genentech, Inc. Detecting longitudinal progression of alzheimer's disease (ad) based on speech analyses
WO2024026472A2 (en) 2022-07-29 2024-02-01 Alector Llc Transferrin receptor antigen-binding domains and uses therefor
WO2024026471A1 (en) 2022-07-29 2024-02-01 Alector Llc Cd98hc antigen-binding domains and uses therefor
CN116948025B (zh) * 2023-09-14 2024-04-02 北京凯祥弘康生物科技有限公司 一种抗Tau蛋白的抗体
CN117106081A (zh) * 2023-09-28 2023-11-24 北京凯祥弘康生物科技有限公司 一种抗nfl蛋白的捕获抗体

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
WO1986005807A1 (en) 1985-04-01 1986-10-09 Celltech Limited Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
ATE120761T1 (de) 1987-05-21 1995-04-15 Creative Biomolecules Inc Multifunktionelle proteine mit vorbestimmter zielsetzung.
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
WO1989009622A1 (en) 1988-04-15 1989-10-19 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
DE68921982T4 (de) 1988-06-14 1996-04-25 Cetus Oncology Corp Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus.
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
IE63847B1 (en) 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
CA2078689C (en) 1990-03-20 2003-02-11 Sherie L. Morrison Chimeric antibodies with receptor binding ligands in place of their constant region
WO1993012227A1 (en) * 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0574395B1 (en) 1990-11-09 2002-06-12 GILLIES, Stephen D. Cytokine immunoconjugates
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
JP3909084B2 (ja) * 1991-10-25 2007-04-25 エヌ・ブイ・インノジェネティクス・ソシエテ・アノニム 微小管結合タンパク質タウに対するモノクローナル抗体
ATE381614T1 (de) 1992-07-24 2008-01-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
US5837821A (en) 1992-11-04 1998-11-17 City Of Hope Antibody construct
ATE236987T1 (de) 1992-11-13 2003-04-15 Idec Pharma Corp Konsensus-kozak-sequenzen zur säugetier- exprimierung
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5843779A (en) 1992-12-14 1998-12-01 N.V. Innogenetics S.A. Monoclonal antibodies directed against the microtubule-associated protein tau, and hybridomas secreting these antibodies
EP0737208B1 (en) 1993-12-21 2006-08-02 Innogenetics N.V. Monoclonal antibodies specific for phf-tau, hybridomas secreting them, antigen recognition by these antibodies and their applications
AU710952B2 (en) 1994-07-29 1999-09-30 Innogenetics N.V. Monoclonal antibodies specific for an epitope of a particular subclass or form of phosphorylated tau, hybridomas secreting them, antigen recognition of these antibodies and their applications
ES2304786T3 (es) 1995-04-27 2008-10-16 Amgen Fremont Inc. Anticuerpos anti-il-8 humanos, derivados a partir de xenoratones inmunizados.
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
WO1998022120A1 (en) 1996-11-19 1998-05-28 The Wistar Institute Of Anatomy & Biology Diagnostic and therapeutic reagents for alzheimer's disease
RO120148B1 (ro) 1997-03-14 2005-09-30 Idec Pharmaceuticals Corporation Sistem vector şi procedeu de inserţie a unui fragment adn, în genomul celulelor de mamifere
EP1724282B1 (en) 1997-05-21 2013-05-15 Merck Patent GmbH Method for the production of non-immunogenic proteins
WO2000030680A1 (en) 1998-11-23 2000-06-02 Idec Pharmaceuticals Corporation Tumor antigen-specific antibody-gp39 chimeric protein constructs
US20040110938A1 (en) 2000-02-24 2004-06-10 Parekh Rajesh Bhikhu Proteins, genes and their use for diagnosis and treatment of schizophrenia
CN1306272C (zh) 2000-11-17 2007-03-21 罗切斯特大学 筛选编码抗原特异性免疫球蛋白分子或其抗原特异性片段的方法
WO2002096948A2 (en) 2001-01-29 2002-12-05 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
WO2002060955A2 (en) 2001-01-29 2002-08-08 Idec Pharmaceuticals Corporation Modified antibodies and methods of use
AT500379B8 (de) 2001-02-02 2009-08-15 Axon Neuroscience Tau-proteine
JP2004538324A (ja) * 2001-08-03 2004-12-24 メディカル リサーチ カウンシル 細胞内抗体
EP1418807B8 (en) 2001-08-24 2008-04-23 Universität Zürich A method of inducing the formation of neurofibrillary tangles in transgenic animals
US20030157641A1 (en) 2001-11-16 2003-08-21 Idec Pharmaceuticals Corporation Polycistronic expression of antibodies
EP1535930B1 (en) 2002-08-14 2010-10-06 Mitsubishi Chemical Medience Corporation Antibody specific to central nervous system tau protein
AU2003276107A1 (en) 2003-04-24 2004-11-19 Universitat Zurich Method of monitoring immunotherapy
CN1871259A (zh) 2003-08-22 2006-11-29 比奥根艾迪克Ma公司 具有改变的效应物功能的经改进的抗体和制备它的方法
WO2005080986A1 (en) 2004-02-18 2005-09-01 University Of Iowa Research Foundation Antibodies to phosphorylated tau, methods of making and methods of use
JP4730584B2 (ja) * 2004-12-06 2011-07-20 東亞合成株式会社 抗菌ペプチド及びその利用
US7083854B1 (en) 2005-05-10 2006-08-01 Cornell Research Foundation, Inc. Fibers from polymer nanoclay nanocomposites by electrospinning
US20080300204A1 (en) 2005-07-19 2008-12-04 University Of Rochester Alpha-Synuclein Antibodies and Methods Related Thereto
WO2007068105A1 (en) 2005-12-12 2007-06-21 Robarts Research Institute Method of diagnosing amyotrophic lateral sclerosis
US8012936B2 (en) * 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
CN103408661B (zh) 2007-01-05 2016-04-06 苏黎世大学 提供疾患特异性结合分子和靶的方法
CA2737267A1 (en) * 2008-09-16 2010-04-08 Simon Fraser University Selective glycosidase inhibitors and uses thereof
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
CA3120504A1 (en) * 2009-06-10 2010-12-16 New York University Immunological targeting of pathological tau proteins
WO2011053565A2 (en) 2009-10-29 2011-05-05 Biomedical Sciences Research Centre "Alexander Fleming" Compositions and methods for detecting a tauopathy
TW201216985A (en) 2010-10-07 2012-05-01 Ac Immune Sa Pharmaceutical composition
JP2014503178A (ja) 2010-10-11 2014-02-13 バイオジェン アイデック インターナショナル ニューロサイエンス ゲーエムベーハー ヒト抗タウ抗体
US20120244174A1 (en) 2011-01-31 2012-09-27 Intellect Neurosciences Inc. Treatment of tauopathies
US8697076B2 (en) 2011-04-27 2014-04-15 Northwestern University Antibodies selective for pathological tau dimers and prefibrillar pathological tau oligomers and their uses in treatment, diagnosis and monitoring of tauopathies
US20120323214A1 (en) 2012-05-16 2012-12-20 Totada R Shantha Alzheimer's disease treatment with multiple therapeutic agents delivered to the olfactory region through a special delivery catheter and iontophoresis
EA035932B1 (ru) 2012-12-21 2020-09-02 Байоджен Ма Инк. Человеческие анти-тау антитела

Also Published As

Publication number Publication date
SG189174A1 (en) 2013-05-31
WO2012049570A1 (en) 2012-04-19
PT2627672T (pt) 2018-11-16
US20210238265A1 (en) 2021-08-05
MX345092B (es) 2017-01-17
EP2627672A1 (en) 2013-08-21
US20190233506A1 (en) 2019-08-01
MX2013003879A (es) 2014-07-09
EP2627672B1 (en) 2018-08-01
BR112013008765B1 (pt) 2022-07-12
US20130295021A1 (en) 2013-11-07
PL2627672T3 (pl) 2018-11-30
US9605059B2 (en) 2017-03-28
CY1120951T1 (el) 2019-12-11
ES2686550T3 (es) 2018-10-18
LT2627672T (lt) 2018-12-10
SI2627672T1 (sl) 2018-10-30
CA2813493A1 (en) 2012-04-19
ZA201303175B (en) 2021-05-26
US8940272B2 (en) 2015-01-27
NZ609984A (en) 2015-05-29
US20120087861A1 (en) 2012-04-12
CA2813493C (en) 2019-07-09
JP2014503178A (ja) 2014-02-13
IL225670B (en) 2018-04-30
TR201812636T4 (tr) 2018-09-21
IL225670A0 (en) 2013-06-27
DK2627672T3 (en) 2018-08-27
CN103339146B (zh) 2017-09-01
CN103339146A (zh) 2013-10-02
US20150252102A1 (en) 2015-09-10
AU2011315181B2 (en) 2016-07-28
US20180002409A1 (en) 2018-01-04
JP6300842B2 (ja) 2018-03-28
EA031698B1 (ru) 2019-02-28
BR112013008765A2 (pt) 2020-09-15
HRP20181320T8 (hr) 2018-12-14
BR112013008765B8 (pt) 2023-05-02
JP2016138102A (ja) 2016-08-04
HRP20181320T1 (hr) 2018-10-19
AU2011315181A1 (en) 2013-05-09

Similar Documents

Publication Publication Date Title
EA201390453A1 (ru) Человеческие анти-тау антитела
PH12021550083A1 (en) Human anti-tau antibodies
EA201490825A1 (ru) Tdp-43-специфически связывающие молекулы
PH12016500658B1 (en) Human anti-alpha-synuclein autoantibodies
CY1122210T1 (el) Ανθρωπινα αντισωματα anti-sod1
EA201590459A1 (ru) Специфические антитела к островковому амилоидному полипептиду человека (hiapp) и их применение
EA201790757A1 (ru) Связывающие антиген cd27l белки
EA201690310A1 (ru) Антитела, связывающие cd27 человека, и их применение
EP3255063A3 (en) Antibodies to matrix metalloproteinase 9
EP3103810A3 (en) Modified variable domain molecules and methods for producing and using them
MX360580B (es) Autoanticuerpos humanos anti-alfa-sinucleina.
CY1120686T1 (el) Αντισωματα ειδικα για το ανθρωπινο πολυπεπτιδιο αμυλοειδους των νησιδιων (ηιαρρ) και χρησεις αυτων